Genetics Shapes Your Health. We Make It Easier to Understand
We analyse key genes and genome-wide markers across Heart, Cancer, Brain, and Metabolic health using NGS and PRS, giving you accurate, population-specific insights.
Loading...
Why It’s Important?
The Stats You Can’t Ignore
CENT AI is built on clinical evidence and not assumptions. These genetic facts explain why early, accurate DNA analysis truly matters.
40–60% of the risk of coronary artery disease (CAD) is estimated to be heritable based on twin and family studies
Source: AHA
What You get with CENT AI?
Decode Your DNA
CENT AI reveals your genetic risks for Heart, Metabolic, Neuro, and Cancer diseases years before symptoms appear.
Cancer
The Cancer panel screens for hereditary predispositions across multiple organs - including breast, ovarian, prostate, colon, pancreatic, endometrial, kidney, skin, thyroid, and brain cancers.
Heart Health
We detect risk for Coronary Artery Disease (CAD), Cardiomyopathies (Hypertrophic, Dilated, Arrhythmogenic), Arrhythmias , and Familial Hypercholesterolemia.
Brain Health
The neuro module focuses on detecting genetic susceptibility to Alzheimer's and Parkinson's disease using PRS and select NGS variants.
Metabolic Health
This module evaluates your genetic tendency for metabolic disorders like Type 2 Diabetes, Obesity, Hypertension, and High Cholesterol.
What all gets covered?
Genetic Risk Profiling Across All Major Disease
Most genetic screening stop at the surface where as CENT AI goes deeper by combining both NGS and PRS. We detect what others often miss
Coronary Artery Disease
Inherited tendency to develop heart blockages or heart attacks.
PRS
What We Test For
PRS measures your genome-wide inherited risk of coronary artery disease, helping estimate your lifetime likelihood of heart blockages
Key Genes Analyzed
Genome-wide SNP markers associated with CAD
Arrhythmogenic Cardiomyopathy
Inherited Scarring of the heart muscle.
NGS
What We Test For
NGS identifies high-impact mutations linked to arrhythmogenic cardiomyopathy, which can increase the risk of ventricular arrhythmias and sudden cardiac events
Key Genes Analyzed
PKP2
DSP
DSG2
DSC2
JUP
LMNA
FLNC
PLN
Long QT Syndrome
A genetic electrical disorder that causes the heart to take longer to reset between beats
NGS
What We Test For
NGS detects pathogenic variants in cardiac ion-channel genes that cause Long QT Syndrome, increasing the risk of fainting and dangerous arrhythmias.
Key Genes Analyzed
KCNQ1
KCNH2
SCN5A
KCNE1
KCNE2
Hypertrophic Cardiomyopathy
Inherited thickening of the heart muscle
NGS
What We Test For
NGS screens for mutations in sarcomere genes that cause hypertrophic cardiomyopathy, helping detect hereditary forms early.
Key Genes Analyzed
MYH7
MYBPC3
TNNT2
TNNI3
TPM1
CTC1
Dilated Cardiomyopathy
A genetic condition where the heart becomes enlarged and weak
NGS
What We Test For
NGS evaluates genes associated with dilated cardiomyopathy, identifying inherited variants that weaken heart muscle function.
Key Genes Analyzed
TTN
LMNA
BAG3
PLN
RBM20
DES
TNNT2
Hypercholesterolemia
Your inherited tendency to have high LDL
PRS
What We Test For
PRS measures your broader genetic tendency for high LDL cholesterol.
Key Genes Analyzed
genome-wide SNP markers for LDL
Alzheimer’s Disease
Long-term risk of memory decline
PRS
What We Test For
PRS estimates your overall genetic susceptibility to late-onset Alzheimer’s by analysing genome-wide markers (including APOE-related signal).
Key Genes Analyzed
PRS: genome-wide SNP markers for Alzheimer’s risk
Parkinson’s Disease
Genetic risk for movement disorder causing tremors, slowness, and stiffness.
PRS
What We Test For
PRS measures your broader genome-wide tendency to develop Parkinson’s later in life. NGS checks for rare inherited mutations that cause familial or early-onset Parkinson’s.
Key Genes Analyzed
PRS:genome-wide SNP markers associated with Parkinson’s disease.
Breast Cancer
Cancer that starts in the breast cells.
NGS
What We Test For
NGS identifies high-impact mutations in genes that raise hereditary breast cancer risk, while PRS measures your broader genome-wide susceptibility to breast cancer.
Key Genes Analyzed
ATM
BARD1
BRCA1
BRCA2
BRIP1
CDH1
CHEK2
MLH1
NBN
NF1
PALB2
PTEN
RAD51C
RAD51D
STK11
TP53
Blood Cancer
Cancers that affect the blood-making cells or immune cells
NGS
What We Test For
NGS identifies high-impact mutations in genes like CEBPA, GATA2 and RUNX1 that predispose to hereditary blood cancers, while PRS (where available) provides a broader genome-wide view of blood cancer susceptibility.
Key Genes Analyzed
CEBPA
GATA2
RUNX1
Colorectal Cancer
Cancer of the colon or rectum, usually starting from small polyps
NGS
What We Test For
NGS detects mutations in mismatch-repair and polyposis genes such as APC, MLH1, MSH2, MSH6, PMS2 and MUTYH, while PRS evaluates your overall inherited tendency for colorectal cancer and polyp formation.
Key Genes Analyzed
APC
BMPR1A
CDH1
CHEK2
EPCAM
MLH1
MSH2
MSH6
MUTYH
PMS2
PTEN
SMAD4
STK11
TP53
GREM1
POLD1
POLE
Endocrine Cancer
Cancer in hormone-producing glands, especially the thyroid
NGS
What We Test For
NGS screens for high-impact variants in endocrine-tumor genes such as MEN1, RET, CDKN2A and VHL, while PRS adds broader genome-wide insight into related endocrine and tumor pathways.
Key Genes Analyzed
AIP
CDC73
CDKN2A
MEN1
PTEN
RET
SDHA
SDHAF2
SDHB
SDHC
SDHD
SMAD4
TMEM127
TP53
VHL
Endometrial / Uterine Cancer
Cancer of the lining of the uterus, usually after abnormal bleeding
NGS
What We Test For
NGS identifies pathogenic variants in EPCAM, MLH1, MSH2, MSH6, PMS2, PTEN and STK11 associated with hereditary endometrial/uterine cancer, while PRS estimates broader genome-wide risk.
Key Genes Analyzed
EPCAM
MLH1
MSH2
MSH6
PMS2
PTEN
STK11
Ovarian Cancer
Inherited mutations that raise ovarian cancer risk
NGS
What We Test For
NGS identifies high-impact mutations in genes such as BRCA1, BRCA2, BRIP1, PALB2 and RAD51C/D that raise hereditary ovarian cancer risk, while PRS uses genome-wide markers to estimate broader susceptibility, often overlapping with breast-cancer risk.
Key Genes Analyzed
BRCA1
BRCA2
BRIP1
DICER1
EPCAM
MLH1
MSH2
MSH6
PALB2
PMS2
RAD51C
RAD51D
STK11
TP53
Pancreatic
Inherited mutations that raise pancreatic cancer risk.
NGS
What We Test For
NGS screens for pathogenic variants in genes such as BRCA2, CDKN2A, PALB2 and SMAD4 that predispose to hereditary pancreatic cancer, while PRS (where available) assesses broader genome-wide risk influences.
Key Genes Analyzed
ATM
APC
BRCA1
BRCA2
CDKN2A
EPCAM
MEN1
MLH1
MSH2
MSH6
PALB2
SMAD4
STK11
TP53
VHL
Prostate Cancer
A common male cancer starting in the prostate gland, often slow-growing
NGS
What We Test For
NGS screens for high-impact variants in genes like BRCA2, BRCA1, ATM, CHEK2 and HOXB13-related pathways (via panel genes) that increase hereditary prostate cancer risk, while PRS measures your broader genome-wide susceptibility to prostate cancer.
Key Genes Analyzed
ATM
BRCA1
BRCA2
MLH1NBN
MLH1
MSH2
MSH6
BRIP1
CHEK2
PMS2
PRKAR1A
SMAD4
SUFU
TP53
VHL
Kidney
Inherited mutations that raise kidney cancer risk.
NGS
What We Test For
NGS detects rare variants in genes such as VHL, BAP1, FH, FLCN and MET associated with hereditary kidney cancer syndromes, while PRS adds genome-wide context for renal cancer risk where data supports it.
Key Genes Analyzed
BAP1
FH
FLCN
MEN1
MLH1
MSH2
MSH6
NF2
PHOX2B
PMS2
PRKAR1A
PTEN
SUFU
TP53
VHL
Skin Cancer
Inherited mutations that raise melanoma and other skin cancer risk.
NGS
What We Test For
NGS evaluates high-impact mutations in genes like CDKN2A, CDK4 and DNA-repair genes, while PRS (where available) estimates broader genome-wide susceptibility to melanoma and other skin cancers.
Key Genes Analyzed
BAP1
BRCA2
CDK4
CDKN2A
ERCC2
ERCC3
ERCC4
ERCC5
PTEN
XPA
XPC
Stomach Cancer
Inherited mutations that raise stomach/gastric cancer risk.
NGS
What We Test For
NGS identifies mutations in genes such as CDH1, APC, BMPR1A, SMAD4 and STK11 associated with hereditary gastric and GI cancer syndromes, while PRS (where data exists) offers additional genome-wide assessment of gastric cancer susceptibility.
Key Genes Analyzed
APC
BMPR1A
CDH1
KIT
MLH1
MSH2
MSH6
PMS2
SDHA
SDHB
SDHC
SMAD4
STK11
High BMI
Genetic risk for high BMI and weight tendency.
PRS
What We Test For
PRS evaluates multiple genome-wide variants that together shape your tendency toward higher BMI, central obesity and weight gain. Know more
Key Genes Analyzed
Genome-wide SNP markers associated with with BMI, adiposity and body-fat distribution.
Hypertension
Genetic risk score for hypertension
PRS
What We Test For
PRS integrates genome-wide markers related to blood pressure and vascular tone, helping quantify your inherited risk for high BP alongside metabolic traits. Know more
Key Genes Analyzed
Genome-wide SNP markers for blood pressure and hypertension.
How Cent AI genetic testing works
The Science Behind Your Genetic Risk
We combine two proven scientific methods NGS to analyse high-impact genes and PRS to study hundreds of thousands of genome-wide markers
Understanding the Two Layers of Genetic Risk
We assess your genetic health using two complementary methods: Next Generation Sequencing (NGS) and Polygenic Risk Scoring (PRS).
NGS
Some monogenic diseases are caused by a single gene carrying a strong mutation. NGS scans clinically important genes to detect these high-impact variants
PRS
Many common conditions are by thousands of tiny genetic variations. PRS analyses hundreds of thousands of genome-wide markers to calculate your overall inherited tendency toward these diseases.
FAQ
Frequently Asked Questions
This screening analyses your DNA across all four major disease systems—Heart, Cancer, Neuro, and Metabolic—using both Next-Generation Sequencing (NGS) for high-impact genes and Polygenic Risk Scoring (PRS) for common, multi-gene risks.
Since your DNA doesn’t change, genetics is typically a once-in-a-lifetime test.
But your personalised screening plan is updated as medical science evolves.
Yes. Genetics allows you to:
Detect risks decades before symptoms
Personalise screening (MRI frequency, calcium score, cancer surveillance, etc.)
Modify lifestyle based on your actual biology
Take early actions that can reduce risk by 30–70%, depending on the condition
Most consumer DNA tests only analyse a few markers or ancestry data.
CENT AI performs clinical-grade sequencing + PRS across thousands of markers and medically important genes—validated for preventive healthcare, not recreation.